GeoVax Labs (NASDAQ:GOVX) Stock Rating Lowered by Wall Street Zen

GeoVax Labs (NASDAQ:GOVX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Monday.

GOVX has been the topic of several other reports. D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of GeoVax Labs in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a research report on Wednesday, April 16th. Finally, Alliance Global Partners cut their price objective on shares of GeoVax Labs from $15.00 to $8.50 and set a “buy” rating on the stock in a research report on Tuesday, April 15th. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, GeoVax Labs currently has a consensus rating of “Moderate Buy” and an average target price of $8.88.

GeoVax Labs Price Performance

GeoVax Labs stock opened at $0.76 on Monday. The firm has a market capitalization of $12.11 million, a price-to-earnings ratio of -0.21 and a beta of 3.36. The company’s 50 day simple moving average is $0.91 and its 200 day simple moving average is $1.29. GeoVax Labs has a fifty-two week low of $0.43 and a fifty-two week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.14. GeoVax Labs had a negative return on equity of 511.96% and a negative net margin of 438.20%. The business had revenue of $1.64 million for the quarter, compared to the consensus estimate of $0.75 million. As a group, analysts predict that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

Large investors have recently made changes to their positions in the stock. Northern Trust Corp acquired a new position in GeoVax Labs in the 4th quarter valued at about $29,000. Jane Street Group LLC acquired a new position in shares of GeoVax Labs in the first quarter valued at approximately $27,000. Geode Capital Management LLC increased its stake in shares of GeoVax Labs by 59.0% during the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after purchasing an additional 33,440 shares during the period. Citadel Advisors LLC acquired a new stake in GeoVax Labs during the 4th quarter worth approximately $104,000. Finally, Armistice Capital LLC acquired a new stake in GeoVax Labs during the 1st quarter worth approximately $703,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.